<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255137</url>
  </required_header>
  <id_info>
    <org_study_id>100203</org_study_id>
    <secondary_id>10-C-0203</secondary_id>
    <nct_id>NCT01255137</nct_id>
  </id_info>
  <brief_title>Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer</brief_title>
  <official_title>Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Adrenocortical carcinoma is an aggressive cancer that starts in the adrenal gland at the&#xD;
      top of the kidneys. It has a low survival rate if standard treatment options are not&#xD;
      effective. Axitinib is an experimental drug that is being studied to determine if it can stop&#xD;
      tumors from growing or make them smaller. Researchers are interested in investigating&#xD;
      axitinib in individuals with aggressive or otherwise untreatable adrenocortical cancer.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To evaluate the effectiveness of axitinib in individuals who have adrenocortical cancer&#xD;
      that is inoperable and has not responded to standard treatments.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals at least 18 years of age who have been diagnosed with adrenocortical cancer&#xD;
      that has not responded to standard treatments.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a full physical examination and medical history, as&#xD;
           well as tumor imaging studies.&#xD;
&#xD;
        -  Participants may have a tumor biopsy prior to starting axitinib.&#xD;
&#xD;
        -  All participants will receive axitinib to take twice a day with food for 28 days (1&#xD;
           cycle). Participants should not drink grapefruit juice or smoke cigarettes while&#xD;
           participating in this study.&#xD;
&#xD;
        -  After the first cycle, the dose may be increased and additional cycles will be given if&#xD;
           the treatment has not had serious side effects.&#xD;
&#xD;
        -  Participants will have regular examinations while taking axitinib, including blood&#xD;
           samples and tumor imaging studies to determine if the tumor has stopped growing. Blood&#xD;
           pressure levels will be carefully monitored during treatment to evaluate potential risk&#xD;
           for high blood pressure.&#xD;
&#xD;
        -  Participants may have a second tumor biopsy 20 to 30 days after treatment begins.&#xD;
&#xD;
        -  Treatment will continue as directed by the study researchers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  The response rates of recurrent, metastatic and unresectable adrenocortical cancer (ACC)&#xD;
           to mitotane, doxorubicin, etoposide, and cisplatin are low and underscore the need for&#xD;
           more effective systemic therapies.&#xD;
&#xD;
        -  VEGF expression and evidence of angiogenesis has been found in many ACCs, so it is&#xD;
           plausible that interfering with vascular endothelial growth factor(VEGF) signaling may&#xD;
           result in anti-tumor activity in patients with ACC.&#xD;
&#xD;
        -  Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial&#xD;
           growth factor (VEGF) receptors 1, 2, and 3. Pre-clinical data suggests that the&#xD;
           anti-tumor activity of axitinib may result from its anti-angiogenic activity and that&#xD;
           this is reversible when treatment is discontinued.&#xD;
&#xD;
        -  Given the known clinical safety and efficacy of axitinib, an assessment of its activity&#xD;
           in ACC and its impact on the VEGF pathway in ACC could provide valuable information.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Determine the response rate of axitinib (AG-013736) in recurrent, metastatic, or primary&#xD;
           unresectable ACC&#xD;
&#xD;
        -  Determine the progression-free survival&#xD;
&#xD;
        -  Explore the relationship of potential biological markers of axitinib activity with&#xD;
           clinical outcomes.&#xD;
&#xD;
        -  Explore the pharmacogenetic analyses of drug metabolism and transport proteins through&#xD;
           germline deoxyribonucleic acid (DNA) examination.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Adults with pathologic confirmation of ACC by the Laboratory of Pathology, National&#xD;
           Cancer Institute (NCI)&#xD;
&#xD;
        -  Diagnosis of recurrent, metastatic, or primary unresectable ACC&#xD;
&#xD;
        -  Measurable disease at presentation&#xD;
&#xD;
        -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2&#xD;
&#xD;
        -  Patients must not have received prior therapy with a tyrosine kinase (TK) inhibitor&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Phase II, open label, non-randomized trial&#xD;
&#xD;
        -  Patients with recurrent, metastatic, or primary unresectable ACC will be given in eight&#xD;
           weeks cycles with BID dosing of axitinib (AG-013736).&#xD;
&#xD;
        -  Patients will be evaluated for response every eight weeks using Response Evaluation&#xD;
           Criteria in Solid Tumors (RECIST) criteria.&#xD;
&#xD;
        -  Tumor biopsies are not mandatory but every attempt will be made to obtain these from&#xD;
           patients prior to starting axitinib and again 20-30 days after treatment has begun.&#xD;
&#xD;
        -  Approximately 40 patients will be needed to achieve the objectives of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC)</measure>
    <time_frame>2 years</time_frame>
    <description>Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10mm. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameter. Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: the appearance of one or more new lesions is also considered progression). Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking s reference the smallest sum diameters while on study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>3/2/11 - 8/2/12</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse events module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Adrenal Cortex Neoplasms</condition>
  <arm_group>
    <arm_group_label>Adrenal Cortex Neoplasms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>5 mg tab orally twice a day with food every 28 days</description>
    <arm_group_label>Adrenal Cortex Neoplasms</arm_group_label>
    <other_name>AG-013736</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Pathologic confirmation of adrenocortical cancer by the Laboratory of Pathology,&#xD;
                  National Cancer Institute (NCI).&#xD;
&#xD;
               2. Measurable disease at presentation.&#xD;
&#xD;
               3. A life expectancy of at least 3 months and Eastern Cooperative Oncology Group&#xD;
                  (ECOG) performance status less than or equal to 2.&#xD;
&#xD;
               4. Age greater than or equal to 18 years.&#xD;
&#xD;
               5. Last dose of chemotherapy or experimental therapy more than 4 weeks (6 weeks in&#xD;
                  the case of nitrosourea) prior to enrollment date; 2 weeks if the last therapy&#xD;
                  was received as part of a phase 0 or exploratory investigational new drug (IND)&#xD;
                  trial. Last surgery more than 4 weeks prior to enrollment, to allow for wound&#xD;
                  healing. Core biopsies or fine needle aspiration (FNA) will not require any&#xD;
                  waiting period.&#xD;
&#xD;
               6. Last radiotherapy treatment 4 weeks prior to starting treatment with this&#xD;
                  protocol and there must be sites of measurable disease that did not receive&#xD;
                  radiation.&#xD;
&#xD;
               7. Prior mitotane therapy is allowed. Patients with a history of a functional tumor&#xD;
                  who are receiving mitotane to control the excess hormone production may continue&#xD;
                  to receive mitotane.&#xD;
&#xD;
               8. Organ and marrow function as defined below:&#xD;
&#xD;
          -  Total bilirubin less than or equal to 1.5 x ULN (upper limit of normal), unless the&#xD;
             patient meets the criteria for Gilbert's Syndrome. The upper limit value for bilirubin&#xD;
             for subjects with Gilbert's Syndrome is less than 3 mg/dl.&#xD;
&#xD;
        Note: A diagnosis of Gilbert's disease will be made in the presence of (1) unconjugated&#xD;
        hyperbilirubinemia noted on several occasions; (2) normal results from complete blood count&#xD;
        (CBC) count, reticulocyte count, and blood smear; (3) normal liver function test results;&#xD;
        and (4) an absence of other disease processes that can explain the unconjugated&#xD;
        hyperbilirubinemia.&#xD;
&#xD;
          -  Aspartate aminotransaminase (AST) less than or equal to 2.5 times ULN, alanine&#xD;
             aminotransaminase (ALT) greater than or equal to 2.5 times ULN&#xD;
&#xD;
          -  Amylase and lipase equal to, or less than, the institutional ULN.&#xD;
&#xD;
          -  Creatinine clearance greater than or equal to 40 ml/min (measured in a timed urine&#xD;
             collection) or serum creatinine less than or equal to 1.6 mg/dl&#xD;
&#xD;
          -  Absolute neutrophil count greater than or equal to 1000/mm^3.&#xD;
&#xD;
          -  Platelet count greater than or equal to 100,000/ mm^3.&#xD;
&#xD;
             9. Ability to understand and sign an informed consent document.&#xD;
&#xD;
             10. Ability and willingness to follow the guidelines of the clinical protocol&#xD;
             including visits to NCI, Bethesda, Maryland for treatment and follow up visits.&#xD;
&#xD;
             11. Because the effects of chemotherapy on the developing human fetus are potentially&#xD;
             harmful, women of childbearing potential and men must agree to use adequate&#xD;
             contraception (hormonal or barrier methods) before, during the study and for a period&#xD;
             of 3 months after the last dose of chemotherapy.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Patients with adrenocortical tumors potentially curable by surgical excision alone as&#xD;
             determined by the Principal Investigator in discussions with the surgical consultants.&#xD;
&#xD;
          2. Patients who have large abdominal masses impinging on bowel or pulmonary masses with&#xD;
             encroached vessels and a potential to bleed will be considered on case by case basis&#xD;
             after careful consultation with multiple disciplines such as radiologists and surgeons&#xD;
             with main intent being patient safety.&#xD;
&#xD;
          3. Unstable hypertension defined as a systolic blood pressure greater than 140 mm Hg or&#xD;
             diastolic pressure greater than 90 mmHg despite optimal medical management and&#xD;
             patients who are receiving more than 1 antihypertensive agent at trial entry, (not&#xD;
             including spironolactone) unless the patient has Cushing's Disease with its associated&#xD;
             hypertension and is well controlled on medications.&#xD;
&#xD;
          4. Untreated brain metastases (or local treatment of brain metastases within the last 6&#xD;
             months) due to the poor prognosis of these patients and difficulty ascertaining the&#xD;
             cause of neurologic adverse events.&#xD;
&#xD;
          5. Pregnancy, due to the possible adverse effects on the developing fetus.&#xD;
&#xD;
          6. Lactating women who are breast-feeding due to the possibility of transmitting axitinib&#xD;
             to the child.&#xD;
&#xD;
          7. The presence of a second malignancy, other than a skin cancer or in situ cervical&#xD;
             cancer because it will complicate the primary objective of the study. Cancer survivors&#xD;
             who have been free of disease for at least two years can be enrolled in this study.&#xD;
&#xD;
          8. Patients with evidence of a bleeding diathesis.&#xD;
&#xD;
          9. Phosphorus level equal to, or less than, the institutional lower limits of normal that&#xD;
             cannot be corrected.&#xD;
&#xD;
         10. Gastrointestinal abnormalities including:&#xD;
&#xD;
               1. inability to take oral medications&#xD;
&#xD;
               2. requirement for intravenous alimentation&#xD;
&#xD;
               3. prior surgical procedure affecting absorption including total gastric resection&#xD;
&#xD;
               4. treatment for active peptic ulcer disease in the past 6 months&#xD;
&#xD;
               5. active gastrointestinal bleeding, unrelated to cancer, as evidenced by&#xD;
                  hematemesis, hematochezia or melena in the past 3 months without evidence of&#xD;
                  resolution documented by endoscopy or colonoscopy&#xD;
&#xD;
               6. malabsorption syndrome&#xD;
&#xD;
         11. Current use or anticipated need for treatment with drugs that are known potent&#xD;
             cytochrome P450 3A4 (CYP3A4) inhibitors (i.e., grapefruit juice, verapamil,&#xD;
             ketoconazole, miconazole, itraconazole, erythromycin, telithromycin, clarithromycin,&#xD;
             indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir,&#xD;
             fosamprenavir, and delavirdine).&#xD;
&#xD;
         12. Current use or anticipated need for treatment with drugs that are known CYP3A4&#xD;
             inducers (i.e., carbamazepine, Phenobarbital, phenytoin, amobarbital, nevirapine,&#xD;
             primidone, rifabutin, rifampin, and St. John's wort).&#xD;
&#xD;
         13. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose&#xD;
             anticoagulants for maintenance of patency of central venous access devise or&#xD;
             prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular&#xD;
             weight heparin is allowed.&#xD;
&#xD;
         14. Active seizure disorder or evidence of brain metastases, spinal cord compression, or&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
         15. Any of the following within 12 months prior to study drug administration: myocardial&#xD;
             infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic&#xD;
             congestive heart failure, cerebrovascular accident or transient ischemic attack and 6&#xD;
             months for deep vein thrombosis or pulmonary embolism.&#xD;
&#xD;
         16. Other severe acute or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration, or may interfere with the interpretation of study results, and in&#xD;
             the judgment of the investigator would make the patient inappropriate for entry into&#xD;
             this study.&#xD;
&#xD;
         17. Current use of drugs that are known inhibitors or inducers of Breast Cancer Resistance&#xD;
             Protein (BCRP) and Organic Anion Transporting Polypeptide (OATP)1B1/3 or known to&#xD;
             affect protein binding should be used with caution and with acknowledgement of the&#xD;
             principal investigator (PI).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio T Fojo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2010-C-0203.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Plager JE. Carcinoma of the adrenal cortex: clinical description, diagnosis, and treatment. Int Adv Surg Oncol. 1984;7:329-53.</citation>
    <PMID>6088397</PMID>
  </reference>
  <reference>
    <citation>Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990 Apr 26;322(17):1195-201.</citation>
    <PMID>2325710</PMID>
  </reference>
  <reference>
    <citation>Cohn K, Gottesman L, Brennan M. Adrenocortical carcinoma. Surgery. 1986 Dec;100(6):1170-7.</citation>
    <PMID>3787475</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>December 4, 2010</study_first_submitted>
  <study_first_submitted_qc>December 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <results_first_submitted>March 7, 2013</results_first_submitted>
  <results_first_submitted_qc>April 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2013</results_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Selective VEGF Inhibitor</keyword>
  <keyword>Clinical Activity</keyword>
  <keyword>Response Rate</keyword>
  <keyword>Measurable Disease</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Adrenocortical Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Cortex Neoplasms</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adrenal Cortex Neoplasms</title>
          <description>Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.&#xD;
Axitinib : 5 mg tab orally twice a day with food every 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adrenal Cortex Neoplasms</title>
          <description>Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.&#xD;
Axitinib : 5 mg tab orally twice a day with food every 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.89" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC)</title>
        <description>Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10mm. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameter. Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: the appearance of one or more new lesions is also considered progression). Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking s reference the smallest sum diameters while on study.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adrenal Cortex Neoplasms</title>
            <description>Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.&#xD;
Axitinib : 5 mg tab orally twice a day with food every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC)</title>
          <description>Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10mm. Partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameter. Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: the appearance of one or more new lesions is also considered progression). Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking s reference the smallest sum diameters while on study.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse events module.</description>
        <time_frame>3/2/11 - 8/2/12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adrenal Cortex Neoplasms</title>
            <description>Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.&#xD;
Axitinib : 5 mg tab orally twice a day with food every 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse events module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adrenal Cortex Neoplasms</title>
          <description>Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.&#xD;
Axitinib : 5 mg tab orally twice a day with food every 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Esophageal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral dysesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social circumstances - Other (auto accident)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="76" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tito Fojo</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-2631</phone>
      <email>FojoT@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

